An interventional study of ENSEAL X1 Curved Jaw in Upper GI; Lower GI; Gynecological, sponsored by Ethicon Endo-Surgery. Completed at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-24.
Sponsored by Ethicon Endo-Surgery (part of Johnson & Johnson) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This prospective, single-arm, multi-center study will collect clinical data in a post-market setting by procedure group (upper gastrointestinal [GI], lower GI, and gynecological). Investigators will perform each procedure using the device in compliance with their standard surgical approach and the ENSEAL X1 Curved Jaw and Generator G11 instructions for use.
The primary objective of this study is to demonstrate the acceptable performance and safety of the ENSEAL X1 Curved Jaw and Generator G11 devices when used per the instructions for use.
Ethicon Endo-Surgery is the lead sponsor of 47 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any upper gastrointestinal/lower gastrointestinal/gynecological procedure where the ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.
Device: ENSEAL X1 Curved Jaw
ENSEAL X1 Curved Jaw is used for vessel transection according to instructions for use.
Number of Vessels With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale
Number of vessels with \<= Grade 3 hemostasis based on hemostasis grading scale were reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with ENSEAL X1; or Grade 4: significant bleeding (example, pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (example, hemoclips, staples, sutures, fibrin sealants, other advanced energy products).
Time frame: On the day of transection (Day 0)
Number of Participants With Device-related Adverse Events (AEs)
Number of participants with device-related AEs were reported. Device-related AEs were those AEs identified as having a relationship of possibly, probably, or causally with the study devices.
Time frame: From Day 0 up to post-procedure follow up visit (up to 28 days)
Number of Participants With Adhesion Removal or Division Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score
Number of participants with adhesion removal or division using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for adhesion removal or division by ENSEAL X1.
Time frame: On the day of transection (Day 0)
Number of Participants With Lymphatics Bundles Division Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score
Number of participants with lymphatics bundles division using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for lymphatic bundles by ENSEAL X1.
Time frame: On the day of transection (Day 0)
Number of Participants With Tissues Bundles Division Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score
Number of participants with tissues bundles division using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues bundles by ENSEAL X1.
Time frame: On the day of transection (Day 0)
Number of Participants With Tissues Grasping Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score
Number of participants with tissues grasping using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues grasping by ENSEAL X1.
Time frame: On the day of transection (Day 0)
Number of Participants With Tissues Cutting Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score
Number of participants with tissues cutting using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues cutting by ENSEAL X1.
Time frame: On the day of transection (Day 0)
Number of Participants With Tissues Dissection Using ENSEAL X1 Device as Assessed by Surgeon Satisfaction Scale Score
Number of participants with tissues dissection using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues dissection by ENSEAL X1.
Time frame: On the day of transection (Day 0)
Number of Vessels With Hemostasis (Grade 1 to 4) Based on Hemostasis Grading Scale
Number of vessels with hemostasis (Grade 1 to 4) based on hemostasis grading scale were reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with ENSEAL X1; or Grade 4: significant bleeding (example, pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (example, hemoclips, staples, sutures, fibrin sealants, other advanced energy products).
Time frame: On the day of transection (Day 0)
Percentage of Grade 4 Vessel Transections Requiring Hemostasis Measures
Percentage of Grade 4 vessel transections requiring hemostasis measures were planned to be reported. Data was not collected and analyzed for this outcome measure because there were no hemostatic grade 4 vessel transections.
Time frame: On the day of transection (Day 0)
| Milestone | ENSEAL X1 Curved Jaw |
|---|---|
| Started | 145 |
| Completed | 145 |
| Not completed | 0 |
Number of vessels with \<= Grade 3 hemostasis based on hemostasis grading scale were reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with ENSEAL X1; or Grade 4: significant bleeding (example, pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (example, hemoclips, staples, sutures, fibrin sealants, other advanced energy products).
| Vessels transected | ENSEAL X1 Curved Jaw |
|---|---|
| Number of Vessels With Less Than or Equal to (<=) Grade 3 Hemostasis Based on Hemostasis Grading Scale | 279 |
Number of participants with device-related AEs were reported. Device-related AEs were those AEs identified as having a relationship of possibly, probably, or causally with the study devices.
| Participants | ENSEAL X1 Curved Jaw |
|---|---|
| Number of Participants With Device-related Adverse Events (AEs) | 2 |
Number of participants with adhesion removal or division using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for adhesion removal or division by ENSEAL X1.
| Participants | ENSEAL X1 Curved Jaw |
|---|---|
| Very Dissatisfied | 0 |
| Dissatisfied | 0 |
| Neither Satisfied or Dissatisfied | 1 |
| Satisfied | 27 |
| Very Satisfied | 21 |
Number of participants with lymphatics bundles division using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for lymphatic bundles by ENSEAL X1.
| Participants | ENSEAL X1 Curved Jaw |
|---|---|
| Very Dissatisfied | 0 |
| Dissatisfied | 0 |
| Neither Satisfied or Dissatisfied | 1 |
| Satisfied | 18 |
| Very Satisfied | 8 |
Number of participants with tissues bundles division using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues bundles by ENSEAL X1.
| Participants | ENSEAL X1 Curved Jaw |
|---|---|
| Very Dissatisfied | 0 |
| Dissatisfied | 0 |
| Neither Satisfied or Dissatisfied | 1 |
| Satisfied | 26 |
| Very Satisfied | 28 |
Number of participants with tissues grasping using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues grasping by ENSEAL X1.
| Participants | ENSEAL X1 Curved Jaw |
|---|---|
| Very Dissatisfied | 0 |
| Dissatisfied | 4 |
| Neither Satisfied or Dissatisfied | 9 |
| Satisfied | 31 |
| Very Satisfied | 23 |
Number of participants with tissues cutting using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues cutting by ENSEAL X1.
| Participants | ENSEAL X1 Curved Jaw |
|---|---|
| Very Dissatisfied | 1 |
| Dissatisfied | 1 |
| Neither Satisfied or Dissatisfied | 3 |
| Satisfied | 38 |
| Very Satisfied | 44 |
Number of participants with tissues dissection using ENSEAL X1 device as assessed by Surgeon Satisfaction scale score were reported. Surgeon satisfaction scale score is a 5-point scale (very dissatisfied, dissatisfied, neither satisfied or dissatisfied, satisfied, or very satisfied) where surgeon rated the use of the device for tissues dissection by ENSEAL X1.
| Participants | ENSEAL X1 Curved Jaw |
|---|---|
| Very Dissatisfied | 0 |
| Dissatisfied | 0 |
| Neither Satisfied or Dissatisfied | 3 |
| Satisfied | 59 |
| Very Satisfied | 45 |
Number of vessels with hemostasis (Grade 1 to 4) based on hemostasis grading scale were reported. A 4-point grading scale was used to assess hemostasis in blood vessels. Grade 1: no bleeding at transection site; Grade 2: minor bleeding at transection site, no intervention needed; Grade 3: minor bleeding at transection site, mild intervention needed, use of compression, monopolar device and/or touch-ups with ENSEAL X1; or Grade 4: significant bleeding (example, pulsatile blood flow, venous pooling) requiring intervention such as extensive coagulation or use of additional hemostatic measures (example, hemoclips, staples, sutures, fibrin sealants, other advanced energy products).
| vessels transected | ENSEAL X1 Curved Jaw |
|---|---|
| Grade 1 | 258 |
| Grade 2 | 12 |
| Grade 3 | 9 |
| Grade 4 | 0 |
Percentage of Grade 4 vessel transections requiring hemostasis measures were planned to be reported. Data was not collected and analyzed for this outcome measure because there were no hemostatic grade 4 vessel transections.
No measurements were reported for this outcome.
Collected over From Day 0 up to post-procedure follow up visit (Up to 28 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ENSEAL X1 Curved Jaw | 0/145 (0%) | 10/145 (6.9%) | 58/145 (40%) |
| Event | ENSEAL X1 Curved Jaw |
|---|---|
| Abdominal painGastrointestinal disorders | 1/145 |
| IleusGastrointestinal disorders | 1/145 |
| Intra-abdominal haematomaGastrointestinal disorders | 1/145 |
| CellulitisInfections and infestations | 1/145 |
| Septic shockInfections and infestations | 1/145 |
| Procedural painInjury, poisoning and procedural complications | 1/145 |
| Vaginal haemorrhageReproductive system and breast disorders | 1/145 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/145 |
| Lymphatic fistulaVascular disorders | 1/145 |
| Pelvic venous thrombosisVascular disorders | 1/145 |
| Event | ENSEAL X1 Curved Jaw |
|---|---|
| NauseaGastrointestinal disorders | 21/145 |
| PainGeneral disorders | 14/145 |
| VomitingGastrointestinal disorders | 10/145 |
| Procedural painInjury, poisoning and procedural complications | 10/145 |
| Abdominal painGastrointestinal disorders | 8/145 |
| ConstipationGastrointestinal disorders | 7/145 |
| IleusGastrointestinal disorders | 4/145 |
| PyrexiaGeneral disorders | 4/145 |
| Abdominal pain upperGastrointestinal disorders | 3/145 |
| Incision site painInjury, poisoning and procedural complications | 3/145 |
| Age, Continuous(Years) | ENSEAL X1 Curved Jaw |
|---|---|
| Mean | 55.28 ± 15.904 |
| Sex: Female, Male(Participants) | ENSEAL X1 Curved Jaw |
|---|---|
| Female | 101 |
| Male | 44 |
| Ethnicity (NIH/OMB)(Participants) | ENSEAL X1 Curved Jaw |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 135 |
| Unknown or Not Reported | 5 |
| Race (NIH/OMB)(Participants) | ENSEAL X1 Curved Jaw |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 133 |
| More than one race | 0 |
| Unknown or Not Reported | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Johnson \& Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu
Data sharing details ↗ · yoda.yale.edu
Ran from Apr 2021 to primary completion in Aug 2023, 28 months.
Results were first posted in Sep 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.